The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Phase 1/2 study of FOG-001, a first-in-class direct ß-catenin:TCF inhibitor, in patients with colorectal cancer, hepatocellular carcinoma, and other locally advanced or metastatic solid tumors.

Kyriakos  Papadopoulos

Consulting or Advisory Role - Basilea; Bicycle Therapeutics; Turning Point Therapeutics

Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Biontech (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); F-star (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kezar Life Sciences (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sensei Biotherapeutics (Inst); Storm Therapeutics (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)

Michael  Cecchini

Stock and Other Ownership Interests  - Parthenon Therapeutics

Honoraria - Agenus; Arcus Biosciences; AstraZeneca; Bayer; BeiGene; Daiichi Sankyo/Astra Zeneca; DAVA Pharmaceuticals; Elevation Oncology; Incendia Therapeutics; Loxo/Lilly; Macrogenics; Modifi Bio; Regeneron; Seagen; Taiho Oncology

Moh'd  Khushman

Stock and Other Ownership Interests  - Cardiff Oncology

Consulting or Advisory Role - Abbvie; bristol-myers squibb; Cardinal Health; Elevar Therapeutics; Exelixis; Muerus; TriSalus Life Sciences

Speakers' Bureau - Caris Life Sciences

Research Funding - Abbvie (Inst); FOGPharma (Inst); IgM Biosciences (Inst); Torl Biotherapeutics (Inst)

Meredith  Pelster

Honoraria - Castle Biosciences (I)

Consulting or Advisory Role - Arcus Biosciences (Inst); AstraZeneca (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Elevation Oncology (Inst); EMD Serono (Inst); Ipsen (Inst); Jazz Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst); Stemline Therapeutics (Inst); Takeda (Inst)

Research Funding - 1200 Pharma (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Affini-T Therapeutics (Inst); Agenus (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Codiak Biosciences (Inst); Compass Therapeutics (Inst); CytomX Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Elevation Oncology (Inst); Elicio Therapeutics (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Fog Pharmaceuticals (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); IMPAC Medical Systems (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Leap Therapeutics (Inst); Neogene (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Panbela Therapeutics (Inst); Revolution Medicines (Inst); Roche (Inst); Seagen (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); Tachyon Therapeutics (Inst); Takeda (Inst); Translational Genomics Research Institute (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)

Jordi  Rodon Ahnert

Consulting or Advisory Role - AADi; Amgen; Bridgebio Pharma; Ellipses Pharma; iOnctura; Mekanistic Therapeutics; Merus; Monte Rosa Therapeutics; Sardona Therapeutics

Research Funding - 280Bio (Inst); AADi (Inst); Adcentrix (Inst); Alnylam (Inst); Alterome (Inst); Amgen (Inst); AstraZenneca (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioTheryX (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cancer Core Europe (Inst); Debiopharm Group (Inst); Exelixis (Inst); Fog Pharmaceuticals (Inst); Fore Biotherapeutics (Inst); Fusion Pharmaceuticals (Inst); GlaxoSmithKline (Inst); Hotspot Pharma (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Immuneering (Inst); Incyte (Inst); Kelun (Inst); Kinnate Biopharma (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); MapKure (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Nuvectis Pharma (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Roche (Inst); Scorpion Therapeutics (Inst); Storm Therapeutics (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Tango Therapeutics (Inst); Tyra Biosciences (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Vividion Therapeutics (Inst); Yingli Pharma (Inst)

Travel, Accommodations, Expenses - 280-Biotech; American Society of Medical Oncology; Dava Oncology; ESMO; Loxo; National Taiwan University Cancer Center; STOP Cancer

Other Relationship - Boxer Capital; Chinese University of Hong Kong; Guidepoint Pharmacy; Sequenom; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social

Shivaani  Kummar

Stock and Other Ownership Interests  - Arxeon Therapeutics (I); Fortress Biotech; PathomIQ

Consulting or Advisory Role - Bayer; BPGBio; Cadila Pharmaceuticals (I); Genome Insight; GI Innovations Inc.; Gilead Sciences; Harbour BioMed; Mirati Therapeutics; Mundipharma; Oxford BioTherapeutics; Seagan; SpringWorks Therapeutics; XY One Therapeutics

Research Funding - Adanate Inc. (Inst); ADC Therapeutics (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Day One Therapeutics (Inst); Deciphera (Inst); Elevation Oncology (Inst); Fog Pharmaceuticals (Inst); Genome & Company (Inst); Gilead Sciences (Inst); GV20 Therapeutics (Inst); Immunitas (Inst); Incyte (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Nuvectis Pharma Inc. (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Transcenta (Inst); Vincerx Pharma (Inst)

Travel, Accommodations, Expenses - Bayer

Rona  Yaeger

Consulting or Advisory Role - Loxo@Lilly; Mirati Therapeutics; Revolution Medicines

Research Funding - Boehringer Ingelheim (Inst); Boundless Bio (Inst); Daiichi Sankyo/UCB Japan (Inst); Mirati Therapeutics (Inst); Pfizer (Inst)

Sunil  Sharma

Stock and Other Ownership Interests  - Barricade Therapeutics; Beta Cat Pharmaceuticals; Black Canyon Bio; ConverGene; Elevar Therapeutics; HLB; Salarius Pharmaceuticals; Stingray Therapeutics

Honoraria - Array BioPharma

Consulting or Advisory Role - Agastiya Biotech; Barricade Therapeutics; Barricade Therapeutics; Barricade Therapeutics; Celularity; Dracen; Elevar Therapeutics; Elevar Therapeutics; Elevar Therapeutics; Incyte; Mirati Therapeutics; Novelty Nobility; Processa Pharmaceuticals, Inc; Rappta Therapeutics; Stemline Therapeutics

Research Funding - AADi; Adagene (Inst); Amal Therapeutics; Celgene; Dracen; Honor Health; Honor Health; Inhibrx; Merck; Nektar; Nimbus Therapeutics (Inst); Novartis; Plexxikon; Sirnaomics; Syndax; Takeda; Tesaro; Toray Industries; Zai Lab

Patents, Royalties, Other Intellectual Property - Compositions and Methods for the Treatment of Cancer. Provisional Application Serial No. 63/270,005.; Compositions and Methods for the Treatment of Coronavirus Infection. Provisional Application Serial No.: 63/005,780. Filing Date: 4/6/2020. TGen Ref No: 200401- 299PROV.; Imidazolopyrazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,954. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV2. Seed Ref. No.: 910255.403P1.; Imidazolopyridazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,951. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV1. Seed Ref. No.: 910255.402P1.; Imidazolotriazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,955. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV3. Seed Ref. No.: 910255.404P1.; Imidazopyridazine and Imidazopyrazine Compounds and Methods of Use Thereof. International PCT Patent Application No.: PCT/US2021/050936.; International PCT Application No. PCT/US20/13618 Title: BISPHOSPHONATE CONJUGATES AND USES THEREOF; Methods and Compounds for Neoantigen Vaccines Provisional Application Serial No.: 63/166,697.; Neoantigen-Informed Tumor-Infiltrating Lymphocyte Cancer Immunotherapy. WO 2021/222855. PCT/US2021/030331; Peptide Inhibitors Targeting the TBL1-Beta-Catenin Complex. Provisional Application Serial No.: 63/159,882; Provisional Application No. 62/961,930. Title: PepSeq as a platform to identify synthetic molecular binding agents; Provisional application number: 62/818,037 Title: Trisubstituted Pyrazolo [1, 5-a] Pyrimidine Compounds and Methods of Use Thereof

Amber  Wells

Employment - Bristol Myers Squibb; Fog Pharmaceuticals

Stock and Other Ownership Interests  - Bristol-Myers Squibb/Celgene

Amanda  Garofalo

Employment - Fog Pharmaceutcials

Stock and Other Ownership Interests  - Arcus Biosciences; Arvinas; Fog Pharmaceutcials; Kymera

Lalith  Akella

Employment - Fog Pharmaceuticals

Stock and Other Ownership Interests  - Fog Pharmaceuticals

Travel, Accommodations, Expenses - Fog Pharmaceuticals

Ziyang  Yu

Employment - Fog Pharmaceuticals

Stock and Other Ownership Interests  - Fog Pharmaceuticals

Patents, Royalties, Other Intellectual Property - Radius health, Inc. Treatment of breast cancer with AR agonist/SARM Constellation pharmaceuticals. Treatment of solid tumors with ARID1A mutation with EZH2 inhibitor

Travel, Accommodations, Expenses - Fog Pharmaceuticals

Varsha  Iyer

Employment - Agios; FOGPharma

Stock and Other Ownership Interests  - Agios

Patents, Royalties, Other Intellectual Property - 1. Mitapivat Therapy and Modulators of Cytochrome P450 2. Methods for Titrating Mitapivat 3. Compounds for Treating MDS-Associated Anemias and other conditions 4. Use of a PK Activator in the treatment of Sickle Cell Disease (Inst)

Marie Huong  Nguyen

Employment - Bristol-Myers Squibb/Celgene; Fog Pharmaceuticals

Stock and Other Ownership Interests  - Bristol-Myers Squibb/Celgene; Fog Pharmaceuticals

Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene; Fog Pharmaceuticals

Keith  Orford

Employment - FOGPharma

Leadership - FOGPharma

Stock and Other Ownership Interests  - FOGPharma

Patents, Royalties, Other Intellectual Property - Patents associated with FOG-001

Travel, Accommodations, Expenses - FOGPharma

Samuel  Klempner

Honoraria - Merck Serono

Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; BeiGene; Daiichi Sankyo/UCB Japan; Eisai; I-Mab; Merck; Novartis; SERVIER; Taiho Oncology

Research Funding - Arcus Biosciences (Inst); BeiGene (Inst); I-Mab (Inst); Leap Therapeutics (Inst); Mersana (Inst)

Other Relationship - Clinical Care Options; NCCN; Research to Practice

(OPTIONAL) Uncompensated Relationships - Debbies Dream Foundation; Hope for Stomach Cancer